Harbin Medisan Pharmaceutical Co., Ltd.

002900

CNE1000032V9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
10.28 ^CNY	-2.28%		+3.63%	-24.69%

04-26	Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	CI
04-26	Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	MT

Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Cash Dividend Proposal for 2021

April 27, 2022 at 08:34 pm

Harbin Medisan Pharmaceutical Co., Ltd. announced the profit distribution proposal for 2021. The company announced final cash dividend/10 shares (tax included) of CCNY 3.20000000.

Latest news about Harbin Medisan Pharmaceutical Co., Ltd.

Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	04-26	CI
Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	04-26	MT
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022, Payable on May 31, 2023	17/05/23	CI
Harbin Medisan Pharma Gets Patent Rights of China Pharmaceutical University-Developed Drug	04/05/23	MT
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	26/04/23	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Management Appointments	28/11/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Implements Final Cash Dividend for 2021, Payable on June 13, 2022	07/06/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend Proposal for 2021	18/05/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Cash Dividend Proposal for 2021	27/04/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/10/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	29/08/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2020, Payable on July 5, 2021	29/06/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020	19/05/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020	28/04/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	27/04/21	CI
Harbin Fuerjia Technology Development Co., Ltd. completed the acquisition of Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd..	28/02/21	CI
Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. for CNY 570 million.	09/02/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	22/10/20	CI

Chart Harbin Medisan Pharmaceutical Co., Ltd.

Duration

Period

Chart Harbin Medisan Pharmaceutical Co., Ltd.

More charts

HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

16/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARBIN MEDISAN PHARMACEUTICAL CO., LTD.	-24.69%	440M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B